Rare diseases

News

Orchard’s MLD gene therapy becomes costliest US medicine

Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-

News

AstraZeneca buys rare disease firm Amolyt for $1.05bn

AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfro

News

NICE no follows Scottish aye for rare disease drug Xenpozyme

NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the U

News

RNA therapy firm Avidity files $400m placement

Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine

News

New film aims to raise awareness of rare disease cALD

Rare Disease Day saw the debut of a film that aims to raise awareness of cerebral adrenoleukodystrophy (cALD), a devastating and fatal condition with no pharmacological tr

News

In U-turn, NICE backs first drug for AL amyloidosis

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has b

Orchard’s MLD gene therapy becomes costliest US medicine

AstraZeneca buys rare disease firm Amolyt for $1.05bn

NICE no follows Scottish aye for rare disease drug Xenpozyme

RNA therapy firm Avidity files $400m placement

New film aims to raise awareness of rare disease cALD

In U-turn, NICE backs first drug for AL amyloidosis

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Rare diseases

Editor's Picks